BBP250117P50000
- 0.00
- 0.000.00%
Virtus Lifesci Biotech Products Etf Newsroom
Crinetics Upgraded to Buy by Jefferies, Atumelnant Potential Cited
J&J Beats in Q4 With in Line Guidance; so Why Is Its Stock Falling?
Intra-Cellular Ticks Higher as J&J Forecasts Early Q2 Close
Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook
Neurocrine Announced Publication Of Supplement On Classic Congenital Adrenal Hyperplasia In The Journal Of Clinical Endocrinology & Metabolism, Covering Clinical, Psychosocial, Treatment Challenge
Top 4 Health Care Stocks You May Want To Dump In Q1
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Trending Stocks as Wall Street Bounces Back With Strong Week
Catalyst Watch: Netflix Earnings, Monster Beverage Event, Drug Data, and Quantum Volatility
Harmony Biosciences Analyst Ratings
Blueprint Medicines Analyst Ratings
Travere Therapeutics Analyst Ratings
10 Health Care Stocks With Whale Alerts In Today's Session
Corporate Candidates to Announce Accelerate Share Buybacks: Trivariate
On the first day of the JPM Medical Conference, pharmaceutical giants are announcing new strategies. Could the mergers and acquisitions in Biomedical begin in 2025?
In 2025, the Biomedical mergers and acquisitions will begin.
Express News | U.S. stock night trading: Hong Kong and A-shares surged! Chinese concept stocks rose together, with Kingsoft Cloud up nearly 8%.
Futu Morning Report | Major new regulations impact AI Chip stocks! NVIDIA and Oracle strongly oppose; Is there a bet that the yield has peaked? Call Bid in U.S. Treasury ETF surges.
Media: NVIDIA's Blackwell chip rack has encountered issues, leading major customers like Microsoft to reduce some Orders; Trump's advisers have proposed a new tariff idea: use the Emergency Economic Powers Act to increase rates by 2-5% monthly; the new US Treasury Secretary's Hold Positions include the S&P 500, Nasdaq, and Bitcoin.
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts
Sage Therapeutics Shares Are Trading Higher After the Company Confirmed the Receipt of an Unsolicited, Nonbinding Proposal From Biogen to Acquire All Outstanding Shares Not Already Owned by Biogen for $7.22 per Share.